Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Biotechnol Prog. 2018 Jul;34(4):1045-1058. doi: 10.1002/btpr.2629. Epub 2018 Mar 31.

Testing the potency of anti-TNF-α and anti-IL-1β drugs using spheroid cultures of human osteoarthritic chondrocytes and donor-matched chondrogenically differentiated mesenchymal stem cells.

Author information

1
Dept. of Biomedical Engineering, Columbia University, New York, USA.
2
Educell Cell Therapy Service Ltd, Trzin, Slovenia.
3
Dept. of Clinical Biochemistry, University of Ljubljana, Slovenia.
4
Celica Biomedical Ltd, Ljubljana, Slovenia.
5
Dept. of Medicine, Columbia University, New York, USA.

Abstract

Inflammation plays a major role in progression of rheumatoid arthritis, a disease treated with antagonists of tumor necrosis factor-alpha (TNF-α) and interleukin 1β (IL-1β). New in vitro testing systems are needed to evaluate efficacies of new anti-inflammatory biological drugs, ideally in a patient-specific manner. To address this need, we studied microspheroids containing 10,000 human osteoarthritic primary chondrocytes (OACs) or chondrogenically differentiated mesenchymal stem cells (MSCs), obtained from three donors. Hypothesizing that this system can recapitulate clinically observed effects of anti-inflammatory drugs, spheroids were exposed to TNF-α, IL-1β, or to supernatant containing secretome from activated macrophages (MCM). The anti-inflammatory efficacies of anti-TNF-α biologicals adalimumab, infliximab, and etanercept, and the anti-IL-1β agent anakinra were assessed in short-term microspheroid and long-term macrospheroid cultures (100,000 OACs). While gene and protein expressions were evaluated in microspheroids, diameters, amounts of DNA, glycosaminoglycans, and hydroxiproline were measured in macrospheroids. The tested drugs significantly decreased the inflammation induced by TNF-α or IL-1β. The differences in potency of anti-TNF-α biologicals at 24 h and 3 weeks after their addition to inflamed spheroids were comparable, showing high predictability of short-term cultures. Moreover, the data obtained with microspheroids grown from OACs and chondrogenically differentiated MSCs were comparable, suggesting that MSCs could be used for this type of in vitro testing. We propose that in vitro gene expression measured after the first 24 h in cultures of chondrogenically differentiated MSCs can be used to determine the functionality of anti-TNF-α drugs in personalized and preclinical studies. © 2018 American Institute of Chemical Engineers Biotechnol. Prog., 34:1045-1058, 2018.

KEYWORDS:

3D tissue spheroids; anti-TNF-α biologicals; human articular chondrocytes; inflammation; mesenchymal stem cells

PMID:
29536646
PMCID:
PMC6138577
[Available on 2019-07-01]
DOI:
10.1002/btpr.2629

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center